Welcome to our dedicated page for Proqr Therapeuti SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProQR Therapeutics N.V. (Nasdaq: PRQR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. ProQR files annual reports on Form 20-F and periodic current reports on Form 6-K, which include press releases, unaudited financial statements, and materials from analyst and investor events. These filings document the evolution of ProQR’s Axiomer RNA editing platform, its clinical and preclinical pipeline, and its financial position over time.
Recent Form 6-K filings referenced by ProQR furnish unaudited financial statements for quarterly periods and press releases such as “ProQR Announces Third Quarter 2025 Operating and Financial Results” and “ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook.” Other 6-Ks include materials from a virtual analyst and investor event focused on the AX-0810 Phase 1 trial design and biomarker strategy, and announcements related to the submission and authorization of a Clinical Trial Application for AX-0810 targeting NTCP.
For investors analyzing PRQR, these filings provide detail on revenue from collaborations, research and development and general and administrative costs, net loss, cash and cash equivalents, deferred income, and other balance sheet items. They also describe ProQR’s strategic collaboration with Eli Lilly, including milestone income and the framework for potential additional targets. Clinical and pipeline-related disclosures in the filings outline the status of programs such as AX-0810, AX-2402, AX-2911, and AX-1412, along with planned milestones and study objectives.
On Stock Titan, ProQR filings are updated in step with EDGAR so users can review new 6-K submissions and other forms as they appear. AI-powered summaries help explain the key points of lengthy documents, highlight important changes in financials, and clarify technical language around RNA editing, clinical trial design, and collaboration terms. Users can quickly navigate to quarterly reports, annual Form 20-F information, and current reports that capture major business and clinical events, supporting deeper due diligence on PRQR’s regulatory and financial disclosures.
Van Herk Investments and affiliated entities report beneficial ownership of 12,202,190 ordinary shares of ProQR Therapeutics N.V., representing 11.6% of the 105,344,052 shares outstanding. The Schedule 13D/A states that Van Herk Investments B.V. purchased 700,195 shares in open market transactions between June 12, 2025 and July 21, 2025 for a total net amount of $1,319,201.27, funded from its general working capital.
The filing adds that on August 19, 2025 Van Herk sent a follow-up letter urging ProQR's board to limit the terms of two directors to the 2026 AGM, explain the rationale for one reappointment, present a board rotation plan and commit to governance standards. The reporting persons state their shares were acquired for investment purposes and reserve the right to engage in communications with management, pursue transactions, buy or sell shares or use derivatives in the future.
Adage Capital Management reports a passive beneficial ownership position in ProQR Therapeutics N.V., holding 6,601,938 ordinary shares, which represents 6.27% of the company's 105,212,527 ordinary shares outstanding (per the company's annual report). The shares are held directly by Adage Capital Partners, L.P., for which Adage Capital Management acts as investment manager, and the filing shows shared voting and shared dispositive power for the reported position.
The Schedule 13G filing is made as a passive disclosure: the Reporting Persons certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing names the reporting entities and key individuals and identifies their principal business address.
ProQR Therapeutics has submitted a Clinical Trial Application (CTA) for a Phase 1 study of AX-0810, a novel drug candidate targeting NTCP (sodium taurocholate co-transporting polypeptide). This regulatory filing marks a significant milestone in the company's drug development pipeline.
Key points from the Form 6-K filing:
- The announcement was made via press release on June 26, 2025
- The filing includes a press release as Exhibit 99.1
- The information is being furnished under Form 6-K and is not considered "filed" under Section 18 of the Securities Exchange Act
- The document was signed by Dennis Hom, Chief Financial Officer
This development represents a strategic advancement in ProQR's clinical program, potentially expanding their therapeutic portfolio. The CTA submission indicates the company is progressing toward clinical trials for AX-0810, which could have implications for investors following ProQR's drug development pipeline.